In vivo viability of extended 4°C‐stored autologous apheresis platelets

Stolla, Moritz; Fitzpatrick, Lynda; Gettinger, Irena; Bailey, S. Lawrence; Pellham, Esther; Christoffel, Todd; Slichter, Sherrill J.

doi:10.1111/trf.14833

Cited by 35 publications

(59 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…10 This study also suggested that there could be a benefit to plasma as storage medium. 10 Based on the 5-to 7-day storage limit for RT-stored platelets, we decided to store platelets in the 4°C test group for 5 days and increase the storage time up to 20 days to exceed our longest previous storage time. Moreover, other groups have published on in vitro performance of 21-day cold-stored platelets in the past and suggested acceptable in vitro performance.…”

Section: Discussionmentioning

confidence: 70%

“…To validate 20‐day cold‐ and plasma‐stored platelets as a transfusion product, we stored platelets in plasma 5, 10, 15, and 20 days at 4°C and included a fresh and 5‐ or 7‐day RT comparator. We had previously published results on 3‐day cold‐stored platelets and compared them to platelets stored at 4°C for 10 and 15 days, respectively . This study also suggested that there could be a benefit to plasma as storage medium .…”

mentioning

confidence: 85%

“…We had previously published results on 3‐day cold‐stored platelets and compared them to platelets stored at 4°C for 10 and 15 days, respectively . This study also suggested that there could be a benefit to plasma as storage medium . Based on the 5‐ to 7‐day storage limit for RT‐stored platelets, we decided to store platelets in the 4°C test group for 5 days and increase the storage time up to 20 days to exceed our longest previous storage time.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Effects of storage time prolongation on in vivo and in vitro characteristics of 4°C–stored platelets

et al. 2020

Self Cite

View full text Add to dashboard Cite

BACKGROUND Cold (4°C)‐stored platelets are currently under investigation for transfusion in bleeding patients. It is currently unknown how long cold‐stored platelets can be stored for clinical applications. STUDY DESIGN AND METHODS Twenty three subjects were recruited. Twenty‐one subjects were available for in vivo assessment and received indium‐111 radiolabeled, cold‐stored platelets. We investigated 5‐ (n = 5), 10‐ (n = 6), 15‐ (n = 5), and 20‐day–stored (n = 5) platelets and obtained samples for in vitro testing at baseline and after the designated storage time. Twenty three units were available for in vitro testing. Five‐ and 7‐day (n = 5 each), room temperature (RT)‐stored platelets served as the current clinical standard control. RESULTS In vivo, we found a continuous decline in platelet recovery from 5 to 20 days. Platelet survival reached a low nadir after 10 days of storage. Ex vivo, we observed the maximum platelet αIIbβ3 integrin response to collagen at 5 days of cold storage, and we saw a continuous decline thereafter. However, platelet integrin activation and mitochondrial membrane integrity were better preserved after 20 days at 4°C, compared to 5 days at RT. Platelet metabolic parameters suggest comparable results between 20‐day cold‐stored platelets and 5‐ or 7‐day RT‐stored platelets. CONCLUSION In summary, we performed the first studies with extended, cold‐stored, apheresis platelets in plasma for up to 20 days with a fresh comparator. Storing cold‐stored platelets up to 20 days yields better results in vitro, but further studies in actively bleeding patients are needed to determine the best compromise between hemostatic efficacy and storage prolongation.

show abstract

Section: Discussionmentioning

confidence: 70%

mentioning

confidence: 85%

mentioning

confidence: 99%

See 1 more Smart Citation

Effects of storage time prolongation on in vivo and in vitro characteristics of 4°C–stored platelets

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…All these solutions contain varying combinations of citrate, phosphate, acetate, magnesium, potassium, gluconate, and glucose, and the ingredients synergistically act to provide anticoagulation, membrane stabilization, metabolic substrates, buffering activity, apoptosis inhibition, and activation inhibition . Recent data has noted that COLD‐PLTs collected and stored in PAS‐F may be significantly superior in in vitro functional assays than PAS‐C–stored COLD‐PLTs, especially when analyzed for their ability to adhere to collagen under flow conditions, although their survival may be inferior to the PAS‐C–stored COLD‐PLTs …”

Section: Cold Pltsmentioning

confidence: 99%

“…33,35 Recent data has noted that COLD-PLTs collected and stored in PAS-F may be significantly superior in in vitro functional assays than PAS-C-stored COLD-PLTs, especially when analyzed for their ability to adhere to collagen under flow conditions, 35 although their survival may be inferior to the PAS-C-stored COLD-PLTs. 36 Several novel additives to PLT storage media are under investigation. These solutions aim to attenuate the storage lesions by reversibly inhibiting PLT activation, preventing the changes in pH and lactate associated with glycolysis, or reducing the risk of pathogen contamination.…”

Section: Cold Pltsmentioning

confidence: 99%

Future of platelet formulations with improved clotting profile: a short review on human safety and efficacy data

Cancelas

2019

Transfusion

View full text Add to dashboard Cite

BACKGROUND Platelet (PLT) transfusion is a widely used therapy in treating or preventing bleeding and hemorrhage in patients with thrombocytopenia or trauma. Compared to the relative ease of PLT transfusion, current practice for PLT storage at room temperature (RT) for up to 5 to 7 days is inefficient, costly, wasteful, and relatively unsafe. STUDY DESIGN AND METHODS This study was a review of major advances in PLT derivative products with improved hemostatic potential and safety feature. RESULTS Recent progress in understanding the PLT activation and host clearance mechanisms has led to reassessments of current and new storage conditions that employ refrigeration and/or cryopreservation to overcome storage lesions and significantly extend shelf life of PLTs with reduced risk of pathogen contamination. DISCUSSION It is anticipated that future PLT preservation involving cold, frozen, and/or pathogen reduction strategies in proper PLT additive solutions will enable longer term and safer PLT storage.

show abstract